Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT00671112
Title Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Brian Hill, MD, PhD

diffuse large B-cell lymphoma

follicular lymphoma

anaplastic large cell lymphoma

chronic lymphocytic leukemia

hairy cell leukemia

primary cutaneous T-cell non-Hodgkin lymphoma

marginal zone B-cell lymphoma

non-Hodgkin lymphoma

lymphoplasmacytic lymphoma

mantle cell lymphoma


Bortezomib + Everolimus

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland Ohio 44195 United States Details
*Shaded cells indicate that there was no data available from for the field